Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Caladrius Biosciences, Inc. (NASDAQ: CLBS).

Full DD Report for CLBS

You must become a subscriber to view this report.


Recent News from (NASDAQ: CLBS)

Caladrius Biosciences' (CLBS) CEO David Mazzo on Q1 2018 Results - Earnings Call Transcript
Caladrius Biosciences, Inc. (CLBS) Q1 2018 Results Earnings Conference Call May 10, 2018, 04:30 PM ET Executives John Menditto - Executive Director, IR & Corporate Communications David Mazzo - President and CEO Joseph Talamo - SVP and CFO Analysts Keay Nakae - Chardan S...
Source: SeekingAlpha
Date: May, 10 2018 18:53
Caladrius Biosciences beats by $0.15
Caladrius Biosciences (NASDAQ: CLBS ): Q1 EPS of -$0.52 beats by $0.15 . Cash, cash equivalents and marketable securities of $53.59M Press Release More news on: Caladrius Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: May, 10 2018 16:09
Caladrius Biosciences Reports 2018 First Quarter Financial Results
BASKING RIDGE, N.J., May 10, 2018 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indicat...
Source: GlobeNewswire
Date: May, 10 2018 16:05
Caladrius Biosciences to Participate at the 15th International Symposium on Cardiovascular Regeneration and Repair
BASKING RIDGE, N.J. , May 07, 2018 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indica...
Source: GlobeNewswire
Date: May, 07 2018 08:00
Caladrius Biosciences to Host First Quarter 2018 Financial Results Conference Call on Thursday, May 10, 2018 at 4:30 p.m. Eastern Time
BASKING RIDGE, N.J., May 03, 2018 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications...
Source: GlobeNewswire
Date: May, 03 2018 08:00
Wired News - Mesoblast Announced Updated Data from Phase-3 and Phase-2b Clinical Trials of MPC-150-IM in Patients with Chronic Heart Failure
Stock Monitor: Caladrius Biosciences Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 20, 2018 / Active-Investors.com has just released a free research report on Mesoblast Ltd (NASDAQ: MESO ). If you want access to this report all you need to do is sign up now by clicking the ...
Source: ACCESSWIRE IA
Date: April, 20 2018 07:20
Your Daily Pharma Scoop: vTv Therapeutics Plunges, Spectrum Provides Updated Data, Selecta Sees Pullback On Data
A nalysis focus: vTv Therapeutics Today we will discuss vTv Therapeutics (VTVT), which has seen three quarters of its market capitalization wiped off after the failure of a late-stage Alzheimer’s study. The failure once again highlights the fact that Alzheimer’s rema...
Source: SeekingAlpha
Date: April, 11 2018 08:00
Caladrius Bio's CLBS12 nabs accelerated review status in Japan for critical limb ischemia
The Japanese Ministry of Health, Labor and Welfare designates  Caladrius Biosciences' ( CLBS -4.3% ) CLBS12 for SAKIGAKE status for the treatment of critical limb ischemia (CLI), a condition characterized by significantly reduced blood flow to the legs and feet due to artery blockage...
Source: SeekingAlpha
Date: April, 10 2018 11:30
Caladrius Biosciences Receives SAKIGAKE Expedited Review Designation in Japan for CLBS12 for Treating Critical Limb Ischemia
BASKING RIDGE, N.J., April 10, 2018 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indicatio...
Source: GlobeNewswire
Date: April, 10 2018 08:00
Caladrius Biosciences to Present at The MicroCap Conference
BASKING RIDGE, N.J., April 03, 2018 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indic...
Source: GlobeNewswire
Date: April, 03 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-155.034.93745.034.7921,374
2018-08-145.115.095.114.9010,656
2018-08-135.08155.125.195.025915,399
2018-08-095.115.235.234.887529,200
2018-08-084.914.9155.114.726243,979

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-153491,47423.6771Cover
2018-08-144191,11037.7477Short
2018-08-133,8009,05341.9750Short
2018-08-101,0409,92110.4828Cover
2018-08-094,84712,72838.0814Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CLBS.


About Caladrius Biosciences, Inc. (NASDAQ: CLBS)

Logo for Caladrius Biosciences, Inc. (NASDAQ: CLBS)

Not available

 

Contact Information

 

 

Current Management

  • Robin Smith / CEO
    • Robin L. Smith, M.D. joined our Board of Directors as its Chairman on August , . She received her M.D. from Yale University and M.B.A. from the Wharton School of Business. During her tenure as CEO of the Caladrius Biosciences, Inc. formerly NeoStem Inc. NASDAQ: CLBS , which she led from to , she pioneered the company s innovative business model, combining proprietary cell therapy development with a contract development and manufacturing organization. Dr. Smith raised over million, completing six acquisitions and one divestiture for which the company won multiple recognition awards. Dr. Smith founded The Stem for Life Foundation SFLF , an educational organization devoted to fostering global awareness of regenerative medicine. In , Dr. Smith forged a partnership with The Vatican to collaboratively create highprofile initiatives to reduce global human suffering. Dr. Smith has served as Chairman of the Board and President of the Stem for life Foundation since its inception and is expanding its mission further under the Cura brand. Dr. Smith also serves on the Boards of Directors of Rockwell Medical NASDAQ: RMTI , Signal Genetics NASDAQ: SGNL , and Bioxcel Corporation. She serves as Vice President and Board member of the STOQ Foundation in Rome and the Board of Overseers at the NYU Langone Medical Center.

Current Share Structure

  • Market Cap: $38,306,139 - 05/15/2018
  • Issue and Outstanding: 9,552,653 - 03/22/2018

 


Recent Filings from (NASDAQ: CLBS)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 24 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 24 2018
Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: April, 02 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 08 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: February, 08 2018

 

 


Daily Technical Chart for (NASDAQ: CLBS)

Daily Technical Chart for (NASDAQ: CLBS)


Stay tuned for daily updates and more on (NASDAQ: CLBS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CLBS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CLBS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of CLBS and does not buy, sell, or trade any shares of CLBS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/